Trial reportBritish journal of clinical pharmacology2026
Effect of dexmedetomidine on cerebral homeostasis in patients undergoing craniotomy for brain tumour excision: A randomized double-blind trial.
Trial report in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of dexmedetomidine on cerebral homeostasis in patients undergoing craniotomy for brain tumour excision: A randomized double-blind trial.British journal of clinical pharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimDexmedetomidine (DEX) seems to hold a potential neuroprotective role, possibly mediated by the attenuation of oxidative stress and neuroinflammation. This study aimed to delineate the effect of DEX used as an adjunct anaesthetic on cerebral oxygenation, cerebral injury and the release of inflammatory markers in brain tumour surgery.
methodsFifty-six patients undergoing craniotomy for brain tumour excision were randomly assigned to receive either DEX (1 μg/kg for 10 min and thereafter 0.7 μg/kg/h) or placebo. Arterial and jugular-bulb blood samples were collected at predefined time-points, whereas a concomitant hemodynamic profile was obtained intraoperatively. S100B protein, neuron-specific enolase (NSE), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) and cortisol levels were determined at baseline and 6 and 24 h postoperatively.
resultsDemographic and perioperative characteristics were comparable between groups. Propofol consumption was considerably reduced in DEX-treated patients (p < 0.001). Measured (jugular-bulb oxygen saturation and partial pressure of oxygen) and estimated (oxygen and carbon dioxide arterial-jugular differences, brain oxygen extraction ratio) cerebral oxygenation indices were favourably affected by DEX infusion (p < 0.05), yet this effect was valid for 15 min (p < 0.05), corresponding to transient systemic hemodynamic augmentation. Moreover, postoperative S100B, NSE, TNF-α, IL-6 and cortisol levels were significantly attenuated in the DEX group (p < 0.01).
conclusionDEX may attenuate the release of cerebral injury and neuroinflammation biomarkers and transiently improve hemodynamics and cerebral oxygenation during brain tumour surgery. Nonetheless, these surrogate effects do not establish clinically relevant neuroprotection, and potential dose-related hemodynamic instability warrants cautious, individualized use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.